When is CA‑125 measurement indicated and how should the results be interpreted?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

CA-125 Measurement: Indications and Interpretation

Primary Indications

CA-125 should be used primarily for monitoring treatment response and detecting recurrence in women with known epithelial ovarian cancer, not as a general screening tool. 1, 2

Screening Context (Limited Role)

  • General population screening is NOT recommended - large trials have not demonstrated mortality benefit from CA-125 screening in average-risk women 2

  • High-risk women only: For women with BRCA1/2 pathogenic variants who decline risk-reducing salpingo-oophorectomy, CA-125 combined with transvaginal ultrasound may be considered starting at age 30-35 years, though this remains suboptimal compared to surgical prevention 1

  • Risk of Ovarian Cancer Algorithm (ROCA): Serial CA-125 measurements every 3-4 months using ROCA interpretation showed improved specificity (99.9%) and positive predictive value (40%) compared to single measurements, with potential for stage shift in high-risk populations 1, 2

Diagnostic Context

  • Pelvic mass evaluation: CA-125 can help stratify risk when an adnexal mass is identified, but has significant limitations due to poor specificity 3

  • Monitoring established ovarian cancer: Most appropriate use is tracking treatment response and detecting recurrence in patients with known disease 4, 5

  • Endometrial cancer risk stratification: Preoperative CA-125 ≥29.1 U/mL independently predicts lymph node metastasis, myometrial invasion ≥50%, and lymphovascular space invasion 6

Interpretation Guidelines

Normal Values - Context Dependent

  • Traditional threshold: 35 U/mL was derived from young blood donors with intact reproductive systems 7

  • Post-treatment baseline: In women after successful treatment for gynecologic malignancy, 95% have CA-125 ≤20 U/mL (median 7.5 U/mL), suggesting 20 U/mL may be more appropriate for surveillance 7

  • Post-treatment elevation: CA-125 ≥35 U/mL after completion of primary treatment independently predicts worse progression-free survival (HR 2.81) and overall survival (HR 6.62) in low-grade serous ovarian cancer 5

Critical Interpretation Pitfalls

Elevated CA-125 does NOT equal ovarian cancer - among women tested for suspected malignancy, only 20% of abnormal results were actually ovarian cancer 3

Common False Positives 3, 8, 9:

  • Other malignancies (26% of false positives): pancreatic, gastrointestinal, endometrial cancers
  • Benign ovarian disease (14%): functional cysts, benign tumors
  • Benign gynecologic conditions (9%): leiomyomas (fibroids), endometriosis (OR 7.96 for false elevation) 9
  • Serosal involvement: peritonitis, cirrhosis, pleural effusion, pericardial effusion - CA-125 is produced by normal peritoneum, pleura, and pericardium 8
  • Smoking: OR 6.62 for falsely elevated HE4; also affects CA-125 interpretation 9
  • Renal impairment: Decreased eGFR significantly elevates HE4 (OR 0.18) and should be considered 9

Specificity Improves with Higher Values

  • CA-125 >1000 kU/L: Substantially higher specificity for ovarian cancer 3
  • Lower values (35-200 U/mL): Highest rate of false positives from benign conditions 3

Post-Surgical Considerations

Do NOT interpret CA-125 in the immediate post-operative period (first 2 weeks) - abdominal surgery itself causes CA-125 elevation independent of tumor burden 10

  • Even after complete tumor removal in early-stage disease, only 14% showed immediate CA-125 decrease 10
  • 18% of patients showed CA-125 increase after complete cytoreduction 10
  • Wait at least 2-4 weeks post-surgery before using CA-125 to assess treatment response 10

Racial and Ethnic Disparities

Current CA-125 thresholds may miss ovarian cancer in racially diverse populations - Black patients have 23% lower odds (AOR 0.77) and American Indian patients 23% lower odds (AOR 0.77) of elevated CA-125 at diagnosis compared to White patients 11

  • This disparity persists even in high-grade serous ovarian cancer (AOR 0.81 for Black patients) 11
  • False-negative CA-125 at diagnosis delays chemotherapy initiation by 9.4 days 11
  • Consider lower thresholds or additional imaging in these populations 11

Practical Algorithm

For Suspected Ovarian Malignancy:

  1. Elevated CA-125 + complex adnexal mass on ultrasound → Refer to gynecologic oncology 1
  2. Elevated CA-125 without mass → Investigate for serosal involvement (ascites, pleural effusion), endometriosis, other malignancies, renal function 8, 9
  3. Normal CA-125 with suspicious mass → Do NOT exclude malignancy; proceed with imaging and surgical evaluation 3, 11

For Surveillance After Treatment:

  1. Establish post-treatment baseline (>2 weeks after surgery) 10
  2. Use 20 U/mL as upper limit of normal for post-treatment surveillance 7
  3. Rising CA-125 trend more significant than single elevated value 2, 5
  4. CA-125 ≥35 U/mL post-treatment warrants investigation for recurrence 5

References

2
Guideline

acr appropriateness criteria® ovarian cancer screening: 2024 update.

Journal of the American College of Radiology, 2025

3
Research

The role of CA125 in clinical practice.

Journal of clinical pathology, 2005

7
Research

What is a normal CA125 level?

Gynecologic oncology, 1994

Related Questions

What does a CA‑125 level of 5.6 U/mL indicate for a patient?
Is a Cancer antigen 125 (CA-125) level of 13.6 U/mL normal and does it require further evaluation?
Which cancer is most strongly associated with an elevated CA-125 (cancer antigen 125) level?
What does an elevated CA‑125 (cancer antigen 125) indicate in a male patient and what diagnostic steps should be taken?
What does a slightly elevated Cancer Antigen 125 (CA 125) level of 48 indicate?
What is the recommended management for transient tachypnea of the newborn (TTN) in neonates?
What are the Navy's limited‑duty patient guidelines, including required clinical evaluation, documentation, specific duty restrictions, treatment protocols, review frequency, and referral criteria for a Medical Evaluation Board?
What is the appropriate treatment for viral labyrinthitis?
What is the recommended post‑exposure prophylaxis (PEP) for HIV in adults, including preferred antiretroviral regimen, dosing, baseline investigations, follow‑up schedule, and adjustments for renal impairment?
What are the nursing skills, procedures, and device considerations for transcatheter aortic valve replacement (TAVR), including system relevance, indications, contraindications, baseline assessment, required supplies, pre‑procedure steps, intra‑procedure steps, post‑procedure care, normal parameters, expected physiologic response, alarms/troubleshooting, complications with nursing interventions, red‑flag signs, ongoing reassessment, and documentation?
How should I evaluate and manage flatulence and abdominal distension in an 8-year-old child?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.